Xeris Biopharma Holdings Inc
XERS
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.2B
Close$
$2.89
60.9% downside
Current Fair Value
60.9% downsideOvervalued by 60.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.20 Billion |
|---|---|
| Enterprise Value | $1.13 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 0.9 |
| Outstanding Shares | 170,523,208 |
Return
| Return on Equity | 92.29% |
|---|---|
| Return on Assets | 3.06% |
| Return on Invested Capital | 11.05% |
Valuation & Multiples
| P/E Ratio | 98.7 |
|---|---|
| PEG | -79.45 |
| Price to Sales | 7.4 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.57 |
| Enterprise Value to EBIT | 37.25 |
| Enterprise Value to Net Income | 93 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 2.87 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.00
Average shareholder expectationRevenue Estimate
$80.67 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$0.02
Average shareholder expectationRevenue Estimate
$90.36 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6946▲ 60.58% |
|---|---|
| Total Calls | 820,600▲ 69.16% |
| Total Puts | 570,000▲ 1222.51% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 65.58%▲ 8.81% |
|---|---|
| Total Invested | $611.09M▼ 22.79% |
| Investors Holding | 243▲ 10.00% |
ESG Score
No data
About Xeris Pharmaceuticals Inc
CEO: paul Edick